Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma of the Oropharynx; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Oral Cavity; Squamous Cell Carcinoma of the Hypopharynx; Squamous Cell Carcinoma of the Paranasal Sinus; Head and Neck Squamous Cell Car cinoma; Squamous Cell Cancer; Head and Neck Carcinoma Interventions: Drug: Nivolumab; Drug: Cetuximab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; James and Esther King Biomedical Research Program; Eli Lilly and Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Erbitux | Hypopharyngeal Cancer | Laryngeal Cancer | Oropharyngeal Cancer | Research | Skin Cancer | Squamous Cell Carcinoma